Back to Search Start Over

Compound Dan Zhi tablet attenuates experimental ischemic stroke via inhibiting platelet activation and thrombus formation.

Authors :
Cheng TF
Zhao J
Wu QL
Zeng HW
Sun YT
Zhang YH
Mi R
Qi XP
Zou JT
Liu AJ
Jin HZ
Zhang WD
Source :
Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2020 Dec; Vol. 79, pp. 153330. Date of Electronic Publication: 2020 Sep 02.
Publication Year :
2020

Abstract

Background: Compound Dan Zhi tablet (DZT) is a commonly used traditional Chinese medicine formula. It has been used for the treatment of ischemic stroke for many years in clinical. However, its pharmacological mechanism is unclear.<br />Purpose: The aim of the current study was to understand the protective effects and underlying mechanisms of DZT on ischemic stroke.<br />Methods: Fifteen representative chemical markers in DZT were determined by ultra-performance liquid chromatography coupled with tandem quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS). The protective effect of DZT against ischemic stroke was studied in a rat model of middle cerebral artery occlusion (MCAO), and the mechanism was further explored through a combination of network pharmacology and experimental verification.<br />Results: Quantitative analysis showed that the contents of phenolic acids, furan sulfonic acids, tanshinones, flavonoids, saponins and phthalides in DZT were calculated as 7.47, 0.788, 0.627, 0.531 and 0.256 mg/g, respectively. Phenolic acids were the most abundant constituents. Orally administered DZT (1.701 g kg <superscript>-1</superscript> ) significantly alleviated the infarct size and neurological scores in MCAO rats. The network analysis predicted that 53 absorbed active compounds in DZT-treated plasma targeted 189 proteins and 47 pathways. Ten pathways were associated with anti-platelet activity. In further experiments, DZT (0.4 and 0.8 mg mL <superscript>-1</superscript> ) markedly inhibited in vitro prostaglandin G/H synthase 1 (PTGS1) activity. DZT (0.4 and 0.8 mg mL <superscript>-1</superscript> ) significantly inhibited in vitro platelet aggregation in response to ADP or AA. DZT (113 and 226 mg kg <superscript>-1</superscript> , p.o.) also produced a marked inhibition of ADP- or AA-induced ex vivo platelet aggregation with a short duration of action. DZT decreased the level of thromboxane A <subscript>2</subscript> (TXA <subscript>2</subscript> ) in MCAO rats. In the carrageenan-induced tail thrombosis model and ADP-induced acute pulmonary thromboembolism mice model, DZT (113 and 226 mg kg <superscript>-1</superscript> , p.o.) prevented thrombus formation. Importantly, DZT (113 and 226 mg kg <superscript>-1</superscript> , p.o.) exhibited a low bleeding liability.<br />Conclusion: DZT protected against cerebral ischemic injury. The inhibition of TXA <subscript>2</subscript> level, platelet aggregation and thrombosis formation might involve in the protective mechanism.<br /> (Copyright © 2020. Published by Elsevier GmbH.)

Details

Language :
English
ISSN :
1618-095X
Volume :
79
Database :
MEDLINE
Journal :
Phytomedicine : international journal of phytotherapy and phytopharmacology
Publication Type :
Academic Journal
Accession number :
32932202
Full Text :
https://doi.org/10.1016/j.phymed.2020.153330